Entity

Time filter

Source Type

Greensboro, NC, United States

Patent
Merz Pharmaceuticals LLC | Date: 2014-06-05

The present invention relates to improved topical gel compositions comprising an active agent, and uses thereof.


Patent
Merz Pharmaceuticals Llc | Date: 2013-01-31

The present invention relates to improved topical gel compositions comprising an active agent, and uses thereof.


Patent
Merz Pharmaceuticals Llc | Date: 2014-01-31

The present invention relates to improved topical gel compositions comprising an active agent, and uses thereof.


Sethi K.D.,University of Georgia | Sethi K.D.,Merz Pharmaceuticals LLC | Rodriguez R.,University of Florida | Olayinka B.,Merz Pharmaceuticals LLC
Journal of Medical Economics | Year: 2012

Objective: Botulinum toxin is widely utilized as a first-line therapy for cervical dystonia (CD). Numerous studies have demonstrated the efficacy and safety of this treatment, but little data exist on patient satisfaction. To address this question, a structured patient survey was conducted in Germany, France, the US, and Canada (n=136 patients with CD). Methods: Specific information was collected on the patients' current and prior botulinum toxin treatment cycles and their overall quality-of-life (including completion of the Cervical Dystonia Impact Profile-58 [CDIP-58]). Results: Patients rated the mean onset of action for their previous injection as 3.8 days, with peak effect at 3.6 weeks and a decline in effects at 9.5 weeks. While most patients were satisfied with their current therapy, only 50.7% were very satisfied, 42.6% were somewhat satisfied, and 6.6% not at all satisfied with their current therapy. Patient satisfaction was lowest just prior to injection and highest at the time of peak effect. Approximately 45% of patients reported that they would prefer a treatment cycle of ≤10 weeks. The mean patient rating of current state of health was above 50 on a visual analog scale from 0 (low) to 100 (high). CDIP-58 results indicated that patients continued to have symptoms on all domains. Conclusions: Botulinum toxin is generally very effective for the treatment of CD. However, this survey indicates that patient satisfaction typically declines prior to re-injection, and many patients may prefer an injection interval of less than the standard 12 weeks. While the survey was based on subjective patient recollections, and the degree to which patient satisfaction is attributable to the control of neurological symptoms remains unclear, prospective studies are clearly warranted to confirm the time course of patient satisfaction and to determine the optimal treatment parameters with botulinum toxins. © 2012 Informa UK Ltd All rights reserved. Source


Patent
Merz Pharmaceuticals LLC | Date: 2015-09-17

The present invention relates to improved topical gel compositions comprising an active agent, and uses thereof.

Discover hidden collaborations